RxDoctor Payments Data

Barbara Muina, MD

Internal Medicine · Miami, FLNPI 1295791531

Payments from drug & device makers

$9,946in general payments, 2019–2025

Across 557 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Medtronic$784
  • Amgen$651
  • AstraZeneca$630
  • GSK$601
  • Lilly USA, LLC$484
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$9,82199%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,946 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$76,116
Medicare patients
142
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide219$245,281
JardianceEmpagliflozin74$78,761
EliquisApixaban90$66,571
MounjaroTirzepatide48$55,059
JanuviaSitagliptin Phosphate55$49,973
TriumeqAbacavir/Dolutegravir/Lamivudi11$46,835
TradjentaLinagliptin57$44,409
FarxigaDapagliflozin Propanediol53$41,633
TivicayDolutegravir Sodium12$30,528
LivaloPitavastatin Calcium39$22,547
VascepaIcosapent Ethyl32$21,389
Breo ElliptaFluticasone/Vilanterol42$19,467
Tresiba Flextouch U-100Insulin Degludec41$19,297
LinzessLinaclotide12$16,068
HumalogInsulin Lispro27$16,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,654$245,281219 claims
Boehringer IngelheimJardiance, Tradjenta$233$123,170131 claims
Lilly USA, LLCMounjaro, Humalog$484$71,06475 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$630$67,249107 claims
PfizerEliquis$192$66,57190 claims
MerckJanuvia$276$49,97355 claims
AbbVieLinzess, Restasis, Synthroid$441$37,094153 claims
GSKBreo Ellipta, Trelegy Ellipta$601$30,22554 claims
Kowa Pharmaceuticals America, Inc.Livalo$168$22,54739 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$212$17,01828 claims
Astellas Pharma US IncMyrbetriq$216$7,97017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →